Contributions
Abstract: P555
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Optical coherence tomography (OCT) of the retina allows for the accurate quantification of different retinal layers. It has previously been shown that both the inner nuclear layer (INL) as well as the peripapillary retinal nerve fiber layer (pRNFL) may reflect disease activity during the course of multiple sclerosis (MS). Here, we measured the impact of different retinal layers on various parameters of disease activity in a prospective manner. To date, 300 patients with early stage relapsing remitting MS (disease duration ≤ 2 years) underwent retinal OCT examination with analysis of the pRNFL and macula layer segmentation. Eyes with past optic neuritis were excluded, all OCT underwent strict quality controls. Primary endpoints consisted of annualized relapse rate (ARR) and progression in expanded disability status scale (EDSS) after 2 years. Secondary endpoints included an annualized increase in T2 lesion load and annualized numbers of Gadolinium enhancing (Gd+) lesions in the cerebral MRI as well as changes in the multiple sclerosis functional composite (MSFC) score, the multiple sclerosis inventory cognition (MUSIC) score and the fatigue scale for motor and cognitive functions (FSMC) after 2 years. In our preliminary results, INL volume at baseline correlated positively with subsequent ARR (p=0.03) and the annualized increase in T2 and Gd+ lesions in cerebral MRI (p< 0.001). pRNFL thickness correlated negatively with the annualized increase in T2 lesion load in cerebral MRI (p=0.02). Progression in EDSS scores after 2 years was by trend associated with lower pRNFL thicknesses (p=0.07). Analysis of the remaining endpoints are pending; more patients are scheduled to finish the study during the next three months. Taken together, our results confirm the role of retinal OCT as a potential prognostic marker in multiple sclerosis. Furthermore, different retinal layers seem to reflect different aspects of disease pathology during the course of MS.
Disclosure:
Benjamin Knier is supported by the Kompetenznetz Multiple Sklerose KKNMS and receives intramural funding from the Technical University Munich.
Paul Schmidt and Lilian Aly have nothing to disclose.
Dorothea Buck has received compensation for activities with Bayer HealthCare, BiogenIdec, MerckSerono, and Novartis. She is supported by the Abirisk Consortium.
Achim Berthele reports grants from Bayer Healthcare, personal fees from Biogen, Merck Serono, Teva, Novartis, and Genzyme, and compensations for clinical trials from Biogen, Novartis, Genzyme, Roche, and Alexion Pharmaceuticals - outside the submitted work.
Mark Muehlau has received research support from Germany ministry for research and education, German Research Foundation, Hertie-Foundation, Merck-Serono, and Novartis.
Bernhard Hemmer has served on scientific advisory boards for Roche, Novartis, Bayer Schering, Merck Serono, Biogen Idec, GSK, Chugai Pharmaceuticals, Micromet, and Genzyme Corporation; he has received speaker honoraria from Bayer Schering, Novartis, Biogen Idec, Merck Serono, Roche, and Teva Pharmaceutical Industries Ltd.; he has received research support from Biogen Idec, Bayer Schering, Merck Serono, Five prime, Metanomics, Chugai Pharmaceuticals, Roche and Novartis
Thomas Korn is supported by the Deutsche Forschungsgemeinschaft DFG (SFB 1054 and TR 128) and by the European Research Council ERC.
Abstract: P555
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Optical coherence tomography (OCT) of the retina allows for the accurate quantification of different retinal layers. It has previously been shown that both the inner nuclear layer (INL) as well as the peripapillary retinal nerve fiber layer (pRNFL) may reflect disease activity during the course of multiple sclerosis (MS). Here, we measured the impact of different retinal layers on various parameters of disease activity in a prospective manner. To date, 300 patients with early stage relapsing remitting MS (disease duration ≤ 2 years) underwent retinal OCT examination with analysis of the pRNFL and macula layer segmentation. Eyes with past optic neuritis were excluded, all OCT underwent strict quality controls. Primary endpoints consisted of annualized relapse rate (ARR) and progression in expanded disability status scale (EDSS) after 2 years. Secondary endpoints included an annualized increase in T2 lesion load and annualized numbers of Gadolinium enhancing (Gd+) lesions in the cerebral MRI as well as changes in the multiple sclerosis functional composite (MSFC) score, the multiple sclerosis inventory cognition (MUSIC) score and the fatigue scale for motor and cognitive functions (FSMC) after 2 years. In our preliminary results, INL volume at baseline correlated positively with subsequent ARR (p=0.03) and the annualized increase in T2 and Gd+ lesions in cerebral MRI (p< 0.001). pRNFL thickness correlated negatively with the annualized increase in T2 lesion load in cerebral MRI (p=0.02). Progression in EDSS scores after 2 years was by trend associated with lower pRNFL thicknesses (p=0.07). Analysis of the remaining endpoints are pending; more patients are scheduled to finish the study during the next three months. Taken together, our results confirm the role of retinal OCT as a potential prognostic marker in multiple sclerosis. Furthermore, different retinal layers seem to reflect different aspects of disease pathology during the course of MS.
Disclosure:
Benjamin Knier is supported by the Kompetenznetz Multiple Sklerose KKNMS and receives intramural funding from the Technical University Munich.
Paul Schmidt and Lilian Aly have nothing to disclose.
Dorothea Buck has received compensation for activities with Bayer HealthCare, BiogenIdec, MerckSerono, and Novartis. She is supported by the Abirisk Consortium.
Achim Berthele reports grants from Bayer Healthcare, personal fees from Biogen, Merck Serono, Teva, Novartis, and Genzyme, and compensations for clinical trials from Biogen, Novartis, Genzyme, Roche, and Alexion Pharmaceuticals - outside the submitted work.
Mark Muehlau has received research support from Germany ministry for research and education, German Research Foundation, Hertie-Foundation, Merck-Serono, and Novartis.
Bernhard Hemmer has served on scientific advisory boards for Roche, Novartis, Bayer Schering, Merck Serono, Biogen Idec, GSK, Chugai Pharmaceuticals, Micromet, and Genzyme Corporation; he has received speaker honoraria from Bayer Schering, Novartis, Biogen Idec, Merck Serono, Roche, and Teva Pharmaceutical Industries Ltd.; he has received research support from Biogen Idec, Bayer Schering, Merck Serono, Five prime, Metanomics, Chugai Pharmaceuticals, Roche and Novartis
Thomas Korn is supported by the Deutsche Forschungsgemeinschaft DFG (SFB 1054 and TR 128) and by the European Research Council ERC.